Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report

Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report

Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to ind...

Full description

Bibliographic Details
Main Authors: Giulia Bonfante, Emanuela Fantinel, Cristina Masini, Franco Bergamaschi, Salvatore Micali, Bernardo Rocco
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Urology Case Reports
Subjects:
Metastatic urothelial carcinoma
Breast metastasis
Immune checkpoint inhibitor
PD-1
Radiotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2214442020303338

Internet

http://www.sciencedirect.com/science/article/pii/S2214442020303338

Similar Items